{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-22-000015","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2022-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.102183+00:00","generated_at":"2026-06-27T15:26:41.773441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evolus reports Q4 preliminary revenue $34.7M (+68% YoY), guides 2022 revenue $143-150M","bullets":["Q4 2021 preliminary net revenue $34.7M, up 68% YoY; full-year 2021 revenue $99.7M, up 76% YoY.","Cash position $146.3M at Dec 31, 2021; expects sufficient funding through cash flow breakeven.","2022 net revenue guidance $143-150M (43-50% growth); adjusted gross margin 58-61% full year, improving to 68-71% in Q4.","Plans to initiate Phase 2 'extra strength' Jeuveau trial in Q1 2022; European Nuceiva launch in Q3 2022.","Added 1,400+ new accounts in 2021; consumer loyalty program reached 270,000+."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-22-000015","json":"https://secwatch.observer/filing/0001570562-22-000015.json","markdown":"https://secwatch.observer/filing/0001570562-22-000015.md","text":"https://secwatch.observer/filing/0001570562-22-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000015/0001570562-22-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000015/eols-20220126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:26:41.773441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}